Welcome. Ongoing research is needed to find treatment options that may help to increase long-term survival for ovarian cancer. That’s why we’ve developed the FAR-131 clinical research study—to investigate a potential treatment for ovarian cancer patients who have relapsed between 6 and 24 months after treatment with a platinum-containing chemotherapy regimen.

 

Thank you for your interest in the FAR-131 study. At this time we are no longer recruiting patients for this study.